UAB 1984: Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and/or Nivolumab

Grant

Date/time Interval

  • November 4, 2020 - November 3, 2024
  • Total Award Amount

  • 206876.00
  • Direct Costs

  • 159135.00
  • Sponsor Award Id

  • Contributor

  • Arnab Basu   Principal Investigator  
  • Lakshminarayanan Nandagopal   Investigator  
  • Mollie Deshazo M.D.   Investigator